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Summary It has been established that loss of tumour suppressor genes is crucial in carcinogenesis. There has
been no reported study on searching for tumour suppressor genes in cholangiocarcinomas as yet. In order to
investigate the loss of heterozygosity (LOH), which may represent such gene loss, in cholangiocarcinoma, we
studied 14 patients with this tumour using restriction fragment length polymorphism analysis. Twenty-two
probes assigned to chromosomes 1, 5, 7, 9, 11, 12, 13, 14, 16, 17 and 18 were used. Allelic losses were found in
chromosomal regions 5q35-qter and l7pl3. Loss of genetic material in these regions in cholangiocarcinoma
was shared with hepatocellular carcinoma. Probes for other chromosomes have as yet shown no consistent
LOH. In conclusion, this study for the first time showed LOH on chromosomes 5 and 17 in cholangiocar-
cinoma.
Cholangiocarcinoma, the intrahepatic bile duct carcinoma, is
thought to arise from the same stem cell as hepatocellular
carcinoma (HCC) (Sell & Dunsford, 1989). Cholangiocar-
cinoma is reported as occurring less frequently than HCC in
most parts of the world. The prognosis of cholangiocar-
cinoma is poor, with the majority of patients dying 6-12
months after diagnosis. The overall survival rate in treated
cases at 5 years is below 9% (Czerniak & Blumgart, 1989).
There is a growing realisation that cancer is a set of
fundamentally genetic diseases (Lasko et al., 1991). Muliple
genetic alterations including the activation of oncogenes and
the inactivation of tumour suppressor genes are important in
carcinogenesis. Tumour suppressor genes are normal cellular
genes whose products are thought to be inhibitors of the
uncontrolled cellular proliferation characteristic of cancer.
Several tumour suppressor genes have been cloned, including
the RBI (Friend et al., 1986), p53 (Oren et al., 1981), WTI
(Call et al., 1990), NFl (Wallace et al., 1990; Viskochil et al.,
1990; Cawthon et al., 1990) and APC (Kinzler et al., 1991a;
Groden et al., 1991) genes. DCC was clones and could prove
to be a candidate suppressor gene (Fearon et al., 1990).
Introduction of a normal tumour suppressor gene, for exam-
ple the RB1 gene, into tumour cells can inhibit tumorigenesis
(Bookstein et al., 1990).
Inactivation of tumour suppressor genes can occur via a
variety of mechanisms including allele loss and mutation.
One of the most widely used techniques for detection of
tumour suppressor gene loss is the demonstration of consis-
tent allele loss or loss of heterozygosity (LOH), in tumour
cells. This is achieved by using a battery of restriction frag-
ment length polymorphism (RFLP) probes to analyse DNAs
from paired samples of non-tumour and tumour tissues
(Lasko et al., 1991). A variety of tumours, including both
childhood and common adult malignancies, exhibit LOH
(Lasko et al., 1991).
Expression of oncogenes, including ras, myc and erbB-2,
and point mutations at K-ras codons 12 and 61 have been
reported in a high proportion of cholangiocarcinomas (Vor-
avud et al., 1989; Tada et al., 1990). Cytogenetic studies on
two cholangiocarcinoma cell lines revealed several chromo-
somal abnormalities (Storto et al., 1990). To our knowledge,
however, there has been no reported study of loss of heter-
ozygosity in cholangiocarcinomas as yet. Here we report the
first study of LOH in cholangiocarcinoma with 22 RFLP
probes assigned to 11 chromosomes.
Materials and methods
Patients andbiopsies
Fourteen patients with cholangiocarcinoma were studied. All
underwent resection of their tumours. None of the patients
received chemotherapy or radiotherapy before surgery. Sur-
gical biopsies from tumoral and non-tumoral liver tissues
were snap frozen in liquid nitrogen at the time of operation.
Lymphocytes from peripheral blood obtained pre-operatively
were also used as a source of normal DNA. Tissue was
stored at - 70°C until DNA extraction. A portion of each
tumour sample was examined histologically to confirm the
type of tumour present.
DNA extraction andanalysis
DNA was prepared from blood and tissue samples by stan-
dard phenol/chloroform methods (Sambrook et al., 1989).
Southern analyses were done as previously described (Ding et
al., 1991). The 22 RFLP probes for chromosomes 1, 5, 7, 9,
11, 12, 13, 14, 16, 17 and 18 and the appropriate restriction
enzymes are listed in Table I. If two alleles appeared as two
separate bands in the resultant autoradiograph of the con-
stitutional DNA, the patient was considered 'informative', or
heterozygous, for the particular marker. Complete deletion
or loss of intensity of one band in the tumour DNA
indicated an allele loss, or an LOH. The loss of band inten-
sity was confirmed by examination of the autoradiographs
with densitometry. A cutoff level of 50% or more of allele
intensity was considered as evidence of LOH.
Results
Table I shows the overall pattern of allele loss in cholan-
giocarcinoma. Overall, 164/229 Southern blots were inform-
ative (heterozygosity: 71.6%) and the overall LOH was 17
out of 164 informative cases (10.4%). Figure 1 shows
representative examples of allele loss.
As shown in Table I, the 14 cholangiocarcinomas had a
higher rate of LOH on chromosomes 5 and 17 than on other
chromosomes. Allelic losses were shown in two out of 14
informative cases (14.3%) for the region of the short arm of
chromosome I (lp33-35) detected by the probe AMSI, three
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Chromosomal Enzyme
Probe region used LOHW
kMSlb 1p33-35 Hinfl 2/14
AMS32 Iq42-43 Alul 3/13
cMS621 5p Hinfl 0/4
ECB27 5q21 BglII 0/5
L5-71 5q21 MspI 0/7
54-D 5q21 MspI 0/6
YN5.48 5q21-22 MspI 0/4
AMS8 5q35-qter Hinfl 3/10
AMS31 7pter-q22 Hinfl 1/13
pAg3 7q31.3-qter Hinfl 0/12
EFD126.3 9q34 PvuII 1/11
H-ras 11p15 BamHI 0/3
pMS51 11ql3 HaeIll 0/7
AMS43 12q24.3-qter Hinfl 1/11
p3.8R 13q14.2 HindlII 0/7
cMS626 13q AluI 0/5
cMS627 14q Alul 0/5
3'HVR 16pl3.3 PvuII 0/8
pulB1148 16q22.1 TaqI 0/3
pl44-D6 17pl3 RsaI 4/9
pYNZ.22 17p13 RsaI 2/5
cMS440 18q HaeIII 0/2
aNo. with LOH/No. of informative cases. bReferences for probes:
AMSI; AMS32, lMS8, XMS31, pkg3 and IMS43: Wong et al., 1987;
cMS621, cMS627 and cMS440: Armour et al., 1990; ECB27: Varesco
et al., 1989; L5-71: Kinzler et al., 1991b; 54-D: Kinzler et al., 1991a;
YN5.48: Nakamura et al., 1988a; EFD126.3: Nakamura et al., 1987;
H-ras: Krontiris et al., 1985; pMS51: Armour et al., 1989; P3.8R:
Friend et al., 1986; 3'HVR: Higgs et al., 1986; pulB1 148: van der
Straten et al., 1983; p144-D6; Kondoleon et al., 1987; pYNZ22:
Nakamura et al., 1988b.
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Figure 1 Representative autoradiographs of Southern hybridisa-
tions with AMS8 (5q35-qter) and pYNZ.22 (17pl3). B = blood
lymphocyte DNA; N = non-tumour tissue DNA; T = tumour tis-
sue DNA. The autoradiographs show allele losses in tumour
DNA (indicated by arrows).
out of 13 (23.1%) for the region of the long arm of
chromosome (lq42-43) by IMS32, three out of 10 (30%)
for 5q35-qter by AMS8, four out of nine (44.4%) at i7pi3 by
p144-D6 and two out of five (40%) also at 17pl3 by
pYNZ22. No consistent allele loss was revealed by any other
probes used in this study.
Previous work on tumours of the colon and rectum has
shown that the chromosome 5 region (5q21-22) encompass-
ing the familial adenomatous polyposis coli (APC) gene and
the mutated in colorectal cancer (MCC) gene is deleted in
inherited and sporadic colorectal cancer (Miyaki et al., 1990;
Ashton-Rickardt et al., 1991). For this reason we compared
the pattern of allele loss in cholangiocarcinoma with that of
secondary liver tumours from colorectal origin using various
Table II Allele loss on chromosome 5 in cholangiocarcinomas and colonic metastases in liver
Probes and regions or genes
cMS621 ECB27 L5-71 54-D YN5.48 lMS8
Patients (5p) (5q2J) (MCC) (APC) (5q2J-22) (5q35-qter)
Cholangiocarcinoma
1 1,2 - 1,2 1,2 1,2 (1),2
2 1,2 1,2 - 1,2 1,2 1,2
3 - 1,2 1,2 - - 1,2
4 1,2 - 1,2 - 1,2 1,2
5 - 1,2 - 1,2 1,2 -
6 1,2 nd 1,2 1,2 - 1,(2)
7 nd 1,2 - - nd 1,2
8 nd 1,2 1,2 - nd 1,(2)
9 nd nd 1,2 1,2 -
10 nd nd 1,2 1,2 nd 1,2
11 nd nd nd - nd 1,2
12 nd nd nd - nd -
13 nd nd nd nd nd
14 nd nd nd nd nd 1,2
Total no 6 7 10 12 7 14
Heterozygosity 4 5 7 6 4 10
Allele loss 0 0 0 0 0 3
Colonic metastasis
15 1,2 - 1,2 1,(2) 1,2 1,2
16 1,2 - (1),2 (1),2 -
17 1,2 - (1),2 _ 1,2
18 1,2 (1),2 - 1,(2) 1,(2) _
19 - - - 1,2 - 1,2
20 1,2 _ (1),2 - 1,(2) (1),2
21 - - - - (1),2 1,(2)
Total no 7 7 7 7 7 7
Heterozygosity 5 1 3 4 5 5
Allele loss 0 1 2 3 4 2
Homozygosity in the constitutional DNA (non-informative pattern (is indicated as a dash; where the
normal tissue was informative the tumour genotype is shown in the table. Heterozygosity is indicated
by 1,2. The continued presence of the larger allelic restriction fragment is indicated by '1' and '2'
indicates continued presence of the smaller allelic fragment. Allele loss (deletion or reduction of
intensity of a band) is indicated by 0. 'nd' indicates no data.
Table I Loss human cholan-LOH IN CHOLANGIOCARCINOMA 1009
probes for chromosome 5q, including a genomic probe L5-
71-3 for MCC and a cDNA probe, 54-D, for APC. Table II
shows that patients with cholangiocarcinoma had no allele
loss when screened with probes mapped to regions of the
chromosome other than 5q35-qter. On the other hand the
majority of patients with hepatic metastases from colorectal
cancers showed allele loss with probes from 5q21-22, the
region of the chromosome associated with colorectal cancer.
Discussion
This is the first study on loss of heterozygosity in cholan-
giocarcinomas. Three out of 22 probes revealed a relatively
high rate of LOH in two chromosomal regions, namely,
5q35-qter (30%) and 17pl3 (44.4% and 40%). There were
also allelic losses at 'p33-35 (2/14, 14.3%), lq42-43 (23.1%),
7pter-q22 (1/13, 7.7%), 9q34 (1/11, 9.1%) and 12q24.3-qter
(1/11, 9.1%), but these lower values might represent random
losses since rapid division ofmalignant cells can produce loss
of heterozygosity at a certain region by chance (Lasko et al.,
1991).
We have previously reported allelic losses at lq42-43 and
17p13 in hepatocellular carcinoma with liver cirrhosis and at
5q35-qter and 17p13 in HCC without liver cirrhosis (Ding et
al., 1991). Hence it is of interest to find LOH at 5q35-qter
and 17p13 in cholangiocarcinoma in this study. It has been
proposed that HCC and cholangiocarcinoma arise from the
same pluripotent liver stem cell (Sell & Dunsford, 1989).
These two types of primary liver malignancies, therefore,
may share similar genetic changes. Allele loss on chromo-
some 17p is shared with other tumours and may be involved
in 'tumour progression' (Sager, 1989; Lasko et al., 1991).
Loss ofheterozygosity at 5q35-qter in both HCC and cholan-
giocarcinoma thus might represent a common genetic change
in the development of the two tumours. Further study is
needed to confirm this finding. This investigation reports the
results of 14 patients collected simultaneously from two
active liver centres over 3 years. The scarcity of this material
highlights the difficulty of surgical resection of intrahepatic
cholangiocarcinoma. Most patients present usually at such an
advanced stage that precludes surgical resection. The familial
adenomatous polyposis coli (APC) gene is located at 5q21
and the gene has been cloned (Kinzler et al., 1991a; Groden
et al., 1991). We previously compared the pattern of allele
loss in non-cirrhotic HCC with that of hepatic metastases
from colorectal cancers using various probe for chromosome
5q (Ding et al., 1991). The majority of LOH in hepatic
metastases from colorectal cancers was found at the region
5q21-22 while the LOH in non cirrhotic HCC was at 5q35-
qter. In the present study on cholangiocarcinomas allele loss
also occurred at 5q35-qter. However, probes from 5q21-22,
including a cDNA probe from APC gene, did not show any
allele loss in cholangiocarcinoma (Tables I and II). The
possible common region involved in both HCC and cholan-
giocarcinoma appears to be distinct from that encompassing
APC. This is supported by the finding that the three patients
exhibiting allele loss at 5q35-qter with the probe AMS8 have
shown no allele loss with the probe 54-D from the APC gene.
There has been no reported direct cytogenetic study as yet
on cholangiocarcinoma tissue. Chromosome study on two
cholangiocarcinoma cell lines showed a number of abnor-
malities (Storto et al., 1990). It is of particular interest that
chromosome 5 was among the most commonly involved
chromosomes in structural abnormalities in both cell lines.
This finding and the results of RFLP analysis in this study
suggest that mutation or deletion of a possible tumour supp-
ressor gene located on chromosome 5, distal to 5q21-22, may
play a role in the development of cholangiocarcinoma.
Recently, loss or mutation of the p53 tumour suppressor
gene at chromosome 17p has been seen at a very high
frequency in a variety of human malignancies (Weinberg,
1991). Loss of heterozygosity occurred in four out of nine
cholangiocarcinoma shown by p144-D6, and in two of five
shown by pYNZ22, in this study. Both probes are assigned
to the region of l7pl3, near the locus of the p53 tumour
suppressor gene. This finding makes it likely that loss of the
p53 gene is also involved in the development ofcholangiocar-
cinoma. It will be of interest to know if there is any overex-
pression of mutant p53 or point mutation of the p53 gene in
cholangiocarcinoma.
In conclusion, this study showed allelic losses on chromo-
somes 5q35-qter and 17pl3 in cholangiocarcinoma. These
losses are shared with HCC.
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